Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial-Reference-Cited by-同舟云学术

Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial

Published:2022-01 Issue:1 Volume:86 Page:104-112
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Blauvelt Andrew,Silverberg Jonathan I.,Lynde Charles W.,Bieber Thomas,Eisman Samantha,Zdybski Jacek,Gubelin Walter,Simpson Eric L.,Valenzuela Fernando,Criado Paulo Ricardo,Lebwohl Mark G.,Feeney Claire,Khan Tahira,Biswas Pinaki,DiBonaventura Marco,Valdez Hernan,Cameron Michael C.,Rojo Ricardo

Publisher

Elsevier BV

Subject

Dermatology

Reference20 articles.

1. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape;Boguniewicz;Ann Allergy Asthma Immunol,2018

2. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial;Bissonnette;Br J Dermatol,2015

3. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis;Bao;JAKSTAT,2013

4. Janus kinases in immune cell signaling;Ghoreschi;Immunol Rev,2009

5. Mediators of chronic pruritus in atopic dermatitis: getting the itch out?;Mollanazar;Clin Rev Allergy Immunol,2016

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

2. EXPERIENCE OF ABROCITINIB IN ATOPIC DERMATITIS;Russian Journal of Skin and Venereal Diseases;2024-09-08

3. Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis;Expert Opinion on Investigational Drugs;2024-08-21

4. Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors;Dermatology and Therapy;2024-08-08

5. Oral Janus Kinase Inhibitors in Pediatric Atopic Dermatitis;Current Allergy and Asthma Reports;2024-08-06